Delivery Order SPE2DB22D1106-SPE2DB24FDVT1
- Not listed
- This is a federal contract award made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,884.78, is for the delivery of Azelastine 0.1% (137 MCG) Spry 30ML, a pharmaceutical product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,029.59 firm fixed-price delivery order is for the supply of Azelastine 0.1% (137 MCG) spray, a pharmaceutical product, with a completion date of November 8, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,234.05 firm fixed-price delivery order is for the supply of Azelastine 0.1% (137 MCG) Spray, a pharmaceutical product. The contract has an ultimate completion date of December 16, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product Azelastine 0.1% (137 mcg) Spray 30 mL. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,922.26 and an ultimate completion date of April 25, 2024. The award is not associated with a set-aside program. Amerisourcebergen Drug Corp's Corporate Office Division has a significant...
- This federal contract award, with ID SPE2DB20D7059|SPE2DB25FPTQ2, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,322.40 firm fixed price delivery order is for the supply of 4566316369 - Azelastine 0.1% (137 MCG) Spray, 30 ML. The contract has an ultimate completion date of November 5, 2024 and was awarded on November 4, 2024. This contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999...
- This is a $3,376.01 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the supply of Azelastine 0.1% (137 MCG) spray, a prescription medication, with a completion date of March 6, 2024. This delivery order is placed under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The $1,392.00 firm fixed price contract is for the supply of 4565433298 - Azelastine 0.1% (137 MCG) Spray, 30ML. It is not a set-aside contract. The delivery order is part of a larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to...
- This federal contract award, with the ID SPE2DX15D1053|SPE2DX24F6PTE, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The $1,149.81 firm fixed price delivery order is for the supply of azelastine 0.1% (137 mcg) spray in 30 ml containers. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary...
- This federal contract award is for the delivery of Azelastine 0.1% (137 MCG) Nasal Spray, 30ML to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract is a firm fixed-price delivery order with a ceiling value of $3,585.39 and an ultimate completion date of December 22, 2023. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Azelastine 0.1% (137 mcg) spray in a 30 ml format, with a ceiling value of $2,352.57. This non-competitive, firm fixed-price delivery order, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a pharmaceutical supply transaction under DLA's medical procurement operations. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB24FDVT1Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,380.72, is for the delivery of Azelastine 0.1% (137 MCG) Spry 30ML, a pharmaceutical product. This is a delivery order contract with a firm fixed price pricing type. The contract has an ultimate completion date of January 19, 2024. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which serves as a critical supplier of pharmaceutical products and medical supplies to various government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2025. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide. The contract award for the Azelastine 0.1% (137 MCG) Spry 30ML is part of this larger IDC. The contract does not have a set-aside designation, indicating it was awarded through full and open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 1/18/24 |